GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
GSK said it would pay €400 million ($430 million) upfront to CureVac to take full control of developing and manufacturing mRNA vaccines for COVID-
Forbes
3 日前